EDISON EQUITY RESEARCH - ATHERSYS
September 30 2014 - 10:56AM
InvestorsHub NewsWire
EDISON EQUITY
RESEARCH: ATHERSYS - AN IMPORTANT PERIOD
Athersys is approaching an important period in the clinical
development of MultiStem, its allogeneic stem cell therapy product.
Enrolment in a Phase II study for ischaemic stroke is expected to
complete within a couple of months and with a 90-day efficacy
endpoint, headline results should be available in Q115. Positive
data could re-rate the stock and ease concerns over the failed
Phase II trial in ulcerative colitis earlier this year. Also in
Q414 a Phase II study in acute myocardial infarction is due to
start, and regulatory approval for a pivotal Phase II/III trial in
GvHD could be secured.
Athersys is a US biotech company developing MultiStem (allogeneic,
bone marrow-derived stem cells). A Phase II trial with MultiStem in
ischaemic stroke is ongoing (data in Q115) and further studies in
AMI (Phase II) and GvHD (Phase II/III) are planned.
To view our full report, please click
here:
http://www.edisoninvestmentresearch.com/research/report/athersys10
Click here to view all of Edison Investment
Research’s published reports
Athersys (NASDAQ:ATHX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Athersys (NASDAQ:ATHX)
Historical Stock Chart
From Apr 2023 to Apr 2024